Influence of marketed herbal menopause preparations on MCF-7 cell proliferation

  title={Influence of marketed herbal menopause preparations on MCF-7 cell proliferation},
  author={Cornelia Bodinet and John V Freudenstein},
Objective:Given the increasing use of alternative menopause treatments, we evaluated the effect of several herbal preparations used for menopause relief on the proliferation of estrogen-sensitive breast cancer cells (MCF-7) as a means of assessing appropriateness for use in women at risk for estrogen-sensitive breast cancer. Design:An MCF-7 cell culture model, as described previously, 1 was used to evaluate the estrogen-agonist and -antagonist activity of commercially available herbal menopause… 
Use of dong quai (Angelica sinensis) to treat peri- or postmenopausal symptoms in women with breast cancer: is it appropriate?
The water extract of dong quai stimulated the growth of MCF-7 cells, possibly dependent of weak estrogen-agonistic activity, and augmented the BT-20 cell proliferation independent of estrogen receptor-mediated pathway.
Black Cohosh: Insights into its Mechanism(s) of Action
It is found that while the most prominent triterpene in BCE, 23-epi-26-deoxyactein, suppresses cytokine-induced nitric oxide production in brain microglial cells, the whole BCE extract actually enhanced this pathway.
Phytotherapy as alternative to hormone replacement therapy.
Phytotherapy will constitute a therapeutic option that can offer assistance to women who want to improve their quality of life through relief of vasomotor symptoms or benefit from other effects for their health.
Breast cancer survivors who use estrogenic botanical supplements have lower serum estrogen levels than non users
Data from this cross-sectional study suggest the use of estrogenic botanical supplements may be associated with sex hormone concentrations in breast cancer survivors, and considering the high use of these supplements among breast cancer patients, further research is needed.
Symptoms and treatment in cancer therapy-induced early menopause.
The epidemiology and diagnosis of hot flashes and the nonpharmacological and pharmacological options for the treatment ofhot flashes, in breast cancer patients in particular are reviewed.
Plant derived alternatives for hormone replacement therapy (HRT)
Abstract Hormone replacement therapy (HRT) has undisputable positive effects on climacteric complaints, in the bone and on body weight but also several undesired side effects. Therefore,
Complementary and alternative medicine use and the menopausal transition : the effect of a Chinese herbal formula on vasomotor symptoms and bone turnover
This thesis investigated issues pertinent to CAM use and the menopausal transition by evaluating the effectiveness of a herbal formula containing Chinese herbs and Cimicifuga racemosa for alleviating vasomotor symptoms, improving quality of life and modulating bone turnover markers.


Influence of Cimicifuga Racemosa on the Proliferation of Estrogen Receptor-Positive Human Breast Cancer Cells
Data that suggest a non-estrogenic, or estrogen-antagonistic effect of CR on human breast cancer cells lead to the conclusion that CR treatment may be a safe, natural remedy for menopausal symptoms in breast cancer.
Soy for breast cancer survivors: a critical review of the literature.
Overall, the data are not impressive that the adult consumption of soy affects the risk of developing breast cancer or that soy consumption affects the survival of breast cancer patients, so it seems reasonable for Breast cancer patients to continue to use soy products.
Estrogenic and antiproliferative properties of genistein and other flavonoids in human breast cancer cells in vitro.
The results reveal that genistein is unique among the flavonoids tested, in that it has potent estrogen agonist and cell growth-inhibitory actions over a physiologically relevant concentration range.
Evaluation of estrogenic activity of plant extracts for the potential treatment of menopausal symptoms.
Genistein was found to be the most effective of four red clover isoflavones tested in the above in vitro assays, suggesting a potential use for some dietary supplements, ingested by human beings, in the treatment of menopausal symptoms.
Estrogenic effects of genistein on the growth of estrogen receptor-positive human breast cancer (MCF-7) cells in vitro and in vivo.
Dietary genistein can act as an estrogen agonist in vivo and in vitro, resulting in the proliferation of cultured human breast cancer cells (MCF-7) and the induction of pS2 gene expression.
Effects of Soy Phytoestrogens Genistein and Daidzein on Breast Cancer Growth
Genistein and daidzein may stimulate existing breast tumor growth and antagonize the effects of tamoxifen, which should be aware of the risks of potential tumor growth when taking soy products.
Effects of soy phytoestrogens genistein and daidzein on breast cancer growth.
Genistein and daidzein may stimulate existing breast tumor growth and antagonize the effects of tamoxifen and women with current or past breast cancer should be aware of the risks of potential tumor growth when taking soy products.
Estrogen and Progestin Bioactivity of Foods, Herbs, and Spices
  • D. ZavaC. DollbaumM. Blen
  • Medicine, Biology
    Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine
  • 1998
It is demonstrated that many of the commonly consumed foods, herbs, and spices contain phytoestrogens and phytoprogestins that act as agonists and antagonists in Vivo.
Growth inhibition of human breast cancer cells by herbs and phytoestrogens.
Epidemiologic studies have suggested that consumption of phytoestrogen-rich foods may protect against breast cancer, and phytoestrogens such as genistein have been reported to both inhibit and
Lack of promotion of estrogen-dependent mammary gland tumors in vivo by an isopropanolic Cimicifuga racemosa extract.
The lack of mammary tumor-stimulating effects of this extract is of great significance in establishing the safety of CR extracts for treatment of menopausal symptoms in women with a history of breast cancer in which hormone-replacement therapy is contraindicated.